| Literature DB >> 34901010 |
Ye Xie1, Jia Yao1,2, Weilin Jin1,3,4, Longfei Ren1,5, Xun Li1,2,4,5,6.
Abstract
Limited by the poor proliferation and restricted sources of adult hepatocytes, there is an urgent need to find substitutes for proliferation and cultivation of mature hepatocytes in vitro for use in disease treatment, drug approval, and toxicity testing. Hepatocyte-like cells (HLCs), which originate from undifferentiated stem cells or modified adult cells, are considered good candidates because of their advantages in terms of cell source and in vitro expansion ability. However, the majority of induced HLCs are in an immature state, and their degree of differentiation is heterogeneous, diminishing their usability in basic research and limiting their clinical application. Therefore, various methods have been developed to promote the maturation of HLCs, including chemical approaches, alteration of cell culture systems, and genetic manipulation, to meet the needs of in vivo transplantation and in vitro model establishment. This review proposes different cell types for the induction of HLCs, and provide a comprehensive overview of various techniques to promote the generation and maturation of HLCs in vitro.Entities:
Keywords: chemical approach; culture system; genetic manipulation; hepatocyte induction; hepatocyte-like cells
Year: 2021 PMID: 34901010 PMCID: PMC8662991 DOI: 10.3389/fcell.2021.765980
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Different methods promoting the maturation of HLCs in vitro as well as various cell sources for HLCs formation. ESCs, embryonic stem cells; iPCSs, included pluripotent stem cells, MSCs, Mesenchymal stem cells; HpSCs, hepatic stem cells; HGF, hepatocyte growth factor; bFGF, basic-fibroblast growth factor.
FIGURE 2Cell sources of HLCs induction in vitro and their advantages (black font) and disadvantages (red font). The abscissa represents the complexity of the stages required during hepatic differentitation. The ordinate represents the potential of cell differentiation into other cell types.
FIGURE 3The flow chat showing the stages of pluripotent stem cells differentiating into HLCs and the common cytokines added at each differentiation stage. HGF, hepatocyte growth factor; EGF, epidermal growth factor; FGF, fibroblast growth factor; OSM, oncostatin M; DEX, dexamethasone.
Hepatocyte-like cells formation by cytokines and growth factors.
| Cell source | Endoderm formation | Hepatic specification | Maturation | Days | Ref. |
|---|---|---|---|---|---|
| Foreskin fibroblast-derived iPSCs | 100 ng/ml Activin A | 1% DMSO | 30 ng/ml OSM | 19 |
|
| 50 ng/ml Wnt3a | 50 ng/ml HGF | ||||
| 10 μmol DEX | |||||
| iPSCs | 10 ng/ml BMP4 | 50 ng/ml BMP4 | 100 ng/ml HGF | 25 |
|
| 10 ng/ml VEGF | 10 ng/ml FGF2 | 20 ng/ml OSM | |||
| 10 ng/ml FGF2 | 10 ng/ml VEGF | 6 μmol Vk | |||
| 10 ng/ml EGF | 100 nmol DEX | ||||
| 20 ng/ml TGF-α | |||||
| 100 ng/ml HGF | |||||
| 100 nmol/L DEX | |||||
| iPSCs | 100 ng/ml Activin A | 20 ng/ml BMP4 | 20 ng/ml HGF | 15 |
|
| 10 ng/ml FGF-2 | 20 ng/ml OSM | ||||
| DEX | |||||
| ESCs | 100 ng/ml Activin A | 20 ng/ml BMP2 | ITS | 22 |
|
| 30 ng/ml FGF4 | 10 ng/ml OSM | ||||
| 2 μmol/L RA | DEX | ||||
| 10 nmol nicotinamide | 20 ng/ml HGF | ||||
| 1 ng/ml b-FGF | |||||
| 100 μmol/L Vc | |||||
| ESCs/iPSCs | 100 ng/ml Activin A | 20 ng/ml BMP4 | 20 ng/ml OSM | 20 |
|
| 10 ng/ml FGF2 | |||||
| 20 ng/ml HGF |
Abbreviation: FGF, 4, fibroblast growth factor 4; HGF, hepatocyte growth factor; IGF, insulin like growth factor; DEX, dexamethasone; OSM, oncostatin M; ITS, insulin/transferrin/selenium; EGF, epidermal growth factor; b-FGF, basic-fibroblast growth factor; DMSO, dimethyl sulfoxide; BMP4, bone morphogenetic protein 4; VEGF, vascular endothelial growth factor; TGF-α, transforming growth factor-α; Vk, vitamin K; RA, retinoic acid; Vc, ascorbic acid.
Small molecules and possible mechanisms in HLCs formation.
| Effect | Small molecules | Mechanism | Cell application | Ref. |
|---|---|---|---|---|
| Endoderm induction | IDE1 | similar to activin A, induces Smad2 phosphorylation and drives AD-MSCs to endoderm formation | AD-MSCs |
|
| CHIR99021 | a specific chemical inhibitor of GSK-3, can induce a rapid increase in the expression of the endoderm makers | AD-MSCs |
| |
| ESCs |
| |||
| iPSCs |
| |||
| 6-bromo-indirubin-3′-oxime (BIO) | a GSK-3 inhibitor, mimics activation of Wnt signaling | ESCs |
| |
| LY294002 | inhibits maintenance of pluripotency and promotes differentiation to endoderm | ESCs |
| |
| Promotion of liver-specific induction and maturation | SJA710-6 | a novel small molecule, can improve the process of hepatic differentiation by regulating the high expression of FOXH1 (FAST1/2) | MSCs |
|
| dimethyl sulfoxide (DMSO) | drives endoderm toward a hepatic fate and promotes maturation | ESCs |
| |
| iPSCs | ||||
| NMSCs |
| |||
|
| ||||
|
| ||||
| Ile-(6) aminohexanoic amide (Dihexa) | an HGF receptor agonist, can promote hepatic maturation | ESCs |
| |
| iPSCs | ||||
| sodium butyrate (SB) | a histone deacetylase inhibitor, results in high levels of hepatic marker expression and reduces cell death | ESCs |
| |
| WJ-MSCs |
| |||
|
| ||||
| SB431542 | a TGF-β inhibitor, is used for the differentiation of progenitors to HLCs | ESCs |
| |
| 5-Azacytidine (5-aza) | a DNA methyltransferase inhibitor, epigenetic changes support the hepatic differentiation | NMSCs |
| |
| Trichostatin A | a histone deacetylase inhibitor, improves hepatocyte phenotype | NMSCs |
| |
| AD-MSC | ||||
| A83-01 | a TGF-β inhibitor, is continuously used to promote hepatocyte differentiation | ESCs |
| |
| iPSCs | ||||
| FH1 and FPH1 | are used to replace HGF and OSM to promote hepatocyte generation | ESCs |
| |
| iPSCs |
Abbreviations: AD-MSC, adipose-derived mesenchymal stem cells; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; MSCs, mesenchymal stem cells; NMSCs, neonatal mesenchymal stromal cell; WJ-MSCs, Wharton’s Jelly-derived mesenchymal stem cells; GSK-3, glycogen synthase kinase 3; TGF-β, transforming growth factor-β; OSM, oncostatin M.
Application of gene editing technology in human HLCs formation.
| Method of modification | Aim | HLCs generation (%) | Advantages | Limits | Example of cell types | Ref. |
|---|---|---|---|---|---|---|
| Lentivirus | overexpression of | ∼28% | induces HLCs directly and saves time and materials | genomic integration | immortalized BM-MSCs |
|
| poor transfection efficiency | ||||||
| overexpression of | N.D. | promotes definitive endoderm differentiation | genomic integration | iPSCs |
| |
| poor transfection efficiency | ||||||
| overexpression of | ∼20% | shows the function of mature hepatocytes | genomic integration | HFF1 |
| |
| proliferation arrest | ||||||
| overexpression of | ∼90% | generates functional HLCs efficiently and reproducibly | genomic integration | HEFs |
| |
| poor transfection efficiency | ||||||
| overexpression of | N.D. | a non-invasive way as seed cells for reprogramming | genomic integration | UCs |
| |
| poor transfection efficiency | ||||||
| Adenovirus | overexpression of | N.D. | promotes definitive endoderm differentiation and improves functionality of HLCs | instability of transgene expression | iPSCs and ESCs |
|
| overexpression of | N.D. | enhances the hepatic functions of HLCs | instability of transgene expression | iPSCs |
| |
| Transfect microRNA mimics | overexpression of miR-122, miR148a, miR-424, miR-542-5p and miR-1246 | N.D. | induces HLCs directly and saves time and materials | long-term effect undefined | UC-MSCs |
|
| Electroporation | overexpression of miR-106a, miR-574-3p and miR-45 | N.D. | induces HLCs directly and save times and materials | cell damage | UC-MSCs |
|
| CRISPR/Cas9 system | PXR-mCherry | N.D. | can be used for identifying factors that increase PXR-mediated drug metabolism and hepatocyte proliferation | hard technique | iPSCs |
|
| target to | N.D. | realizes enrichment of high-functioning human iPSC-derived HLCs | hard technique | iPSCs |
|
Abbreviations: BM-MSCs, bone marrow-derived mesenchymal stem cells; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; UC-MSCs, umbilical cord-derived mesenchymal stem cells; HEFs, human embryonic fibroblasts; HFF1, human fetal limb fibroblasts, UCs, urinary epithelial cells; N.D., no data.
FIGURE 4Applicaton and Challenges of HLCs, BAL, bioartificial liver.